Interview with Tapani Sura, General Manager, Astellas Poland
You were appointed general manager of Astellas Poland in early 2006, only a bit after Astellas Pharma Inc. was established, on April 1, 2005 through the merger of the mother…
Address: Osmanska 14 str.
02-823 Warsaw
Poland
Tel: +48 22 545 11 11
Over the past ten years, Astellas has built a strong position in Urology, Transplantation, and Antibiotics in the Polish market.
Therapy Areas
Transplantation
Urology
Dermatology
Gastroenterology
A Brief History
Astellas Pharma Sp. z o.o. was registered in August 2005 after the merger of the mother companies Yamanouchi and Fujisawa. Its predecessor, Yamanouchi Pharma Sp. z o.o., began its operation in 1999. Before that the business was handled through the Warsaw branch office of Yamanouchi, which was opened in 1992. Fujisawa Branch Office was opened in 2000.
Local Pharmaceutical Market Conditions
After a fast period of growth from 1991 to 2002, the Polish pharmaceutical market has become turbulent because of fast and sometimes unpredictable changes in reimbursement, pricing, and regulations. This has been the case especially when it comes to innovative pharma companies. As a matter of fact, apart from sartans, the last NCEs entered the reimbursement list in 1998. The policy of the Ministry of Health has been and still is to support local industry and generics producers. However, the size of the country (close to 40 million people) still makes it an attractive market.
Astellas Pharma Europe Ltd. is focused on five key therapeutic areas: Transplantation, Urology, Dermatology, Anti-infectives, and Pain Management. In addition, Astellas remains committed to improving the lives of patients with a number of other diseases, including Diabetes and Cardiovascular, CNS, Respiratory, and Gastrointestinal. As an organisation, Astellas is focused on and committed to its R&D programmes and is driven by its philosophy of enriching the lives of people around the world.
You were appointed general manager of Astellas Poland in early 2006, only a bit after Astellas Pharma Inc. was established, on April 1, 2005 through the merger of the mother…
As east area director for the vast CEE market, Pawel Mazur explains how Accord Healthcare has gone from strength to strength in Poland, with the intention of becoming a top…
Krzysztof Popławski, general manager of Baxter Poland, discusses the Baxter Education Center, the largest educational program for a European affiliate, and its role in raising the awareness within the Polish…
Hubert Niemyjski, country manager of Coloplast Poland and the Baltics, highlights the large differences between the market landscape of the company’s three pillars; ostomy, wound and continence care. Additionally, he…
Olympus is internationally well-regarded as being a quality camera provider and continues to provide developed countries across the globe with high-tech medical devices from endoscopes to imagery solutions. Tomasz Mrzygłód,…
Paweł Migdalski, CEO at Siemens Healthineers Poland, discusses the innovations they are bringing to the market and how they are building on the success of the Siemens Healthineers Academy. Furthermore,…
Tomasz Dzitko, founder and CEO of Delfarma, Poland’s leading parallel importer, gives an overview of the sector in Poland and its impact on the healthcare ecosystem, as well as the…
Piotr Steczniewski, president of Profarm PS – a successful wholesale family business – since 2012, shares how the company has managed to thrive over the years through constant adaptation to…
Łukasz Korybalski, regional manager of Becton Dickinson (BD) Central Eastern Europe, discusses the rising significance of the region as the company continues to grow and the strategic importance of Poland,…
Marzena Kulis, managing director of Johnson & Johnson Medical Devices CEE, highlights the importance of the region and Poland within J&J Medical Devices, and the impact of increasing healthcare expenditures…
Despite the global R&D excitement around oncology, cardiovascular death still remains the world’s largest killer, and according to OECD data, accounts for roughly a third of all mortalities. This trend…
Cezary Kilczewski, president and founder of Medicofarma, a Polish CMO, discusses the company’s recent upgrades to double production capacity and the move into R&D operations as well as the dynamics…
Andrzej Schonert, CEO of Synoptis Industrial, discusses the intricacies of the Polish market and the requirement to move into niche areas, mainly in Rx, to concentrate their pharmaceutical offering to…
See our Cookie Privacy Policy Here